REFERENCES
- Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl. l):S37–S40.
- Khedmat H, Ahmadzad-Asl M, Amini M, . Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc. 2007;39(4):1003–1007.
- Gold CH, Morley JE, Viljoen M, . Gastric acid secretion and serum gastrin levels in patients with chronic renal failure on regular hemodialysis. Nephron. 1980;25:92.
- Muto S, Murayama N, Asano Y, . Hypergastrinemia and achlorhydria in chronic renal failure. Nephron. 1985;40:143.
- Ghonaimy E, Barsoum R, Soliman M, . Serum gastrin in chronic renal failure: morphological and physiological correlation. Nephron. 1985;39:86.
- Paronen I, Ala-Kaila K, Rantala I, . Gastric parietal, chief, and G-cell densities in chronic renal failure. Scand J Gastroenterol. 1991;26:696–700.
- Fisher RS, Lipshutz W, Cohen S. The hormonal regulation of pyloric sphincter function. J Clin Invest. 1973;52:1289.
- Sugimoto M, Yamaoka Y. Review of Helicobacter pylori infection and chronic renal failure. Ther Apher Dial. 2011;15(1):1–9.
- Ozgur O, Boyacioglu S, Ozdogan M, . Helicobacter pylori infection in hemodialysis patients and renal transplant recipients. Nephrol Dial Transplant. 1997;12:289–291.
- Davenport A, Shallcross TM, Crabtree JE, . Prevalence of Helicobacter pylori in patients with end-stage renal failure and renal transplant recipients. Nephron. 1991;59:597–601.
- Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009;75:96–103.
- Chong VH. Impact of duration of hemodialysis on gastrointestinal symptoms in patients with end stage renal failure. J Gastrointestin Liver Dis. 2010;19(4):462–463.
- Flobert C, Cellier C, Berger A, . Right colonic involvement is associated with severe forms of ischemic colitis and occurs frequently in patients with chronic renal failure requiring hemodialysis. Am J Gastroenterol. 2000;95(1): 195–198.
- Dalle IJ, Maes BD, Geboes KP, . Crohn’s-like changes in the colon due to mycophenolate? Colorectal Dis. 2005;7:27–34.
- Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009;22:737–743.
- Papadimitriou JC, Cangro CB, Lustberg A, . Histologic features of mycophenolate mofetil-related colitis: a graft versus host disease-like pattern. Int J Surg Pathol. 2003;11:295–302.
- Kim HC, Park SB. Mycophenolate mofetil-induced ischemic colitis. Transplant Proc. 2000;32:1896–1897.
- European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321–1325.
- Calvo N, Sanchez-Fructuoso AI, Conesa J, . Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc. 2006;38:2396–2397.
- Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int. 2004;17(10):609–616.
- Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14:353–380.